Finance

Lists
Why is CHRS down 4.44%?
Dive Deeper
CHRS:NASDAQ
Coherus Oncology Inc
$0.51
-4.44%
(-0.024) 1D
Nov 13, 10:55:33 AM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CHRS...
Open
$0.53
High
$0.54
Low
$0.50
Mkt. cap
79.30M
Avg. vol.
2.02M
Volume
1.75M
52-wk high
$2.62
52-wk low
$0.50
EPS
-$0.98
Beta
1.03
Shares outstanding
154.54M
No. of employees
145
Open
$0.53
High
$0.54
Low
$0.50
Mkt. cap
79.30M
Avg. vol.
2.02M
Volume
1.75M
52-wk high
$2.62
52-wk low
$0.50
EPS
-$0.98
Beta
1.03
Shares outstanding
154.54M
No. of employees
145
News stories
From web sources and news partners
About Coherus Oncology Inc
CEODennis Lanfear
Employees145
Founded2010
HeadquartersRedwood City, California, United States
SectorHealth Care
IndustryBiotechnology
Websitecoherus.com
Analyst ratings
Based on 3 analysts giving stock ratings to CHRS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for CHRS in the last 3 months.
Highest
Current $0.51
$8.00 (+1,454.61%)
Average
$6.33 (+1,130.08%)
Lowest
$4.00 (+677.30%)
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Jeng
Guggenheim
Buy
Maintained
$8.00
+1,454.6%
11/09/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$7.00
+1,260.3%
11/10/2026
Jason McCarthy
Maxim Group
Buy
Reiterated
$4.00
+677.3%
10/30/2026
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
$7.00
+1,260.3%
09/21/2026
Jay Olson
Oppenheimer
Buy
Maintained
$10.00
+1,843.3%
08/06/2026
Michael Nedelcovych
TD Cowen
Buy
Maintained
-
-
05/28/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
12.75M
12.31M
14.31M
14.27M
Cost of goods sold
4.04M
3.81M
4.24M
4.09M
Cost of revenue
4.04M
3.81M
4.24M
4.09M
Research and development expenses
30.97M
21.54M
21.45M
22.61M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
21.01M
23.10M
20.95M
21.22M
Operating expense
51.98M
44.65M
42.40M
43.83M
Total operating expenses
56.03M
48.46M
46.64M
47.92M
Operating income
-43.28M
-36.15M
-32.33M
-33.65M
Other non operating income
-5.22M
1.40M
1.31M
918.00K
EBT including unusual items
-46.35M
-36.94M
-33.35M
-38.88M
EBT excluding unusual items
-43.75M
-36.94M
-33.35M
-35.51M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-37.64M
-38.33M
-20.63M
-39.33M
Net profit margin
-295.29%
-311.35%
-144.20%
-275.56%
Earnings per share
-0.34
-0.25
-0.19
-0.20
Interest and investment income
7.00M
-
-
-
Interest expense
-2.25M
-2.19M
-2.32M
-2.78M
Net interest expenses
4.75M
-2.19M
-2.32M
-2.78M
Depreciation and amortization charges
-
-
-
-
EBITDA
-42.38M
-35.27M
-31.47M
-32.80M
Gain or loss from assets sale
-338.32M
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps